Cecilie Bahnsen Reimagines PORTER's Nylon Bags With Laser-Cut Florals
Leading the collection is the backpack, available in an all-black nylon twill and decorated with black-on-black embroidery throughout the body and laser-cut flowers — Bahnsen's signature. The 2 Way Tool Bag, offered in classic olive green Khaki, a baby Gratian Blue, and Black, is a more directional silhouette, combining the likenesses of an elegant handbag and a tool carrier into one model. Finally, the smallest piece is the Bonsac Mini, offered in the same colorways, with a scaled-down design.
On the new collaboration, Bahnsen said, 'This is a romantic act. It's about sorting through memories while deciding what to keep and what to reconstruct,' in a statement. Highlighting the power of quiet charm over flashy displays, Bahnsen's monochrome approach gives PORTER's durable nylon fabrics the spotlight. Simultaneously, the romantic sensibilities of the collection represent a contemporary facet of PORTER's visual identity as it inches towards 100 years in business.
The Cecilie Bahnsen x PORTER collection is set for release on June 5 at PORTER's flagship store, PORTER SHINJUKU, andYoshida & Co.'s web store.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
One in eight high earners with no inheritance ‘trapped by financial outgoings'
One in eight (12%) people with a salary over £100,000, but with no parental wealth to fall back on, feel 'trapped' by their current financial commitments, a survey has found. More than two-fifths (44%) do not feel that they are able to comfortably meet their financial commitments each month, according to the research commissioned by wealth manager Killik & Co. Despite their high salaries, nearly a fifth (18%) of high earners in this group admit that their financial commitments are causing them stress and anxiety. Over a quarter (28%) said that the cost of supporting loved ones is reducing their financial savings while 26% said their own personal financial commitments are impacting their financial cushion. The most common monthly financial commitment, aside from household expenses and utility bills, was insurance (66%), including health, home and car cover. Nearly half (47%) of those surveyed have commuting costs, and 45% have private healthcare or other medical expenses. Over a third (36%) have credit card debt to pay. This group is also largely focused on the short term, the research indicated, with the majority (56%) thinking only a year ahead when planning finances and only 3% planning more than five years in advance. Will Stevens, head of wealth planning, Killik & Co said: 'A high tax burden, loss of free childcare, family dependants and mortgage costs all stack up and make it difficult for even those on the highest salaries to build up financial resilience. 'If they are not due an inheritance, it's clear even those on six figures and above are struggling to build up savings to ensure longer-term financial stability for their family. 'Provided money is managed carefully, this doesn't need to be the case. Upweighting pension contributions, managing salary increases and childcare support, and seeking financial advice to ensure your estate is well structured from a tax perspective, can all help high earners avoid the common traps which block them from accumulating wealth.' More than 2,000 people across the UK who are earning £100,000 or more and do not stand to inherit money from parents and whose parents cannot support them financially were surveyed by Censuswide for the research carried out in April and May. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
13 hours ago
- CNBC
Trump, EU's von der Leyen to meet on Sunday to try to clinch a trade deal
European Commission President Ursula von der Leyen is set to meet U.S. President Donald Trump on Sunday to clinch a trade deal for Europe that would likely see a 15% baseline tariff on most EU goods, but end months of uncertainty for EU companies. U.S. and EU negotiators huddled in final talks on tariffs facing crucial sectors like cars, steel, aluminium and pharmaceuticals before the meeting, which is expected at 1530 GMT on Trump's golf course in Turnberry, western Scotland. U.S. Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick flew to Scotland on Saturday and EU Trade Commissioner Maros Sefcovic arrived on Sunday morning. Lutnick told "Fox News Sunday" that the EU needed to open its markets for more U.S. exports to convince Trump to reduce a threatened 30% tariff rate that is due to kick in on Aug. 1. "The question is, do they offer President Trump a good enough deal that is worth it for him to step off of the 30% tariffs that he set," Lutnick said, adding that the EU clearly wanted — and needed — to reach an agreement. A separate U.S. administration official was upbeat that a deal was possible. "We're cautiously optimistic that there will be a deal reached," the official said, speaking on condition of anonymity. "But it's not over till it's over." The EU deal would be a huge prize, given that the U.S. and EU are each other's largest trading partners by far and account for a third of global trade. Ambassadors of EU governments, on a weekend trip to Greenland organized by the Danish presidency of the EU, held a teleconference with EU Commission officials on Sunday to agree on the amount of leeway von der Leyen would have. In case there is no deal and the U.S. imposes 30% tariffs on Aug. 1, the EU has prepared counter-tariffs on 93 billion euros ($109 billion) of U.S. goods. EU diplomats have said a deal would likely include a broad 15% tariff on EU goods imported into the U.S., mirroring the U.S.-Japan trade deal, along with a 50% tariff on European steel and aluminium for which there could be export quotas. EU officials are hopeful that a 15% baseline tariff would also apply to cars, replacing the current 27.5% auto tariff. Some expect the 27-nation bloc may be able to secure exemptions from the 15% baseline tariff for its aerospace industry and for spirits, though probably not for wine. The EU could also pledge to buy more liquefied natural gas from the U.S., a long-standing offer, and boost investment in the United States. Trump told reporters there was "not a lot" of wiggle room on the 50% tariffs that the U.S. has on steel and aluminium imports, adding, "because if I do it for one, I have to do it for all." The U.S. president, in Scotland for a few days of golfing and bilateral meetings, told reporters upon his arrival on Friday evening that von der Leyen was a highly respected leader and he was looking forward to meeting with her. He said there was a 50-50 chance that the two sides could reach a framework trade pact, adding that Brussels wanted to "make a deal very badly." The EU now faces U.S. tariffs on more than 70% of its exports, with 50% on steel and aluminium, an extra 25% on cars and car parts on top of the existing 2.5% and a 10% levy on most other EU goods. EU officials have said a "no-deal" tariff rate of 30% would wipe out whole chunks of transatlantic commerce. A 15% tariff on most EU goods would remove uncertainty but would be seen by many in Europe as a poor outcome compared to the initial European ambition of a zero-for-zero tariff deal on all industrial goods. Seeking to learn from Japan, which secured a 15% baseline tariff with the U.S. in a deal earlier this week, EU negotiators spoke to their Japanese counterparts in preparation for Sunday's meeting. For Trump, aiming to reorder the global economy and reduce decades-old U.S. trade deficits, a deal with the EU would be the biggest trade agreement, surpassing the $550 billion deal with Japan. So far, he has reeled in agreements with Britain, Japan, Indonesia and Vietnam, although his administration has failed to deliver on a promise of "90 deals in 90 days."
Time Business News
18 hours ago
- Time Business News
New Advances in IAHA Injections for Orthopedic Care
Orthopedic intra-articular hyaluronic acid (IAHA) injection is a treatment where a natural substance found in hyaluronic acid-format fluid is injected into a joint, most commonly to relieve pain, pain, pain and improve mobility in patients with chronic osteoarthritis. The future of orthopedic intra-articular hyaluronic acid (IAHA) injection market looks promising the future, cases of increasing osteoarthritis, the patient's priority for non-surreal treatment, and is inspired by innovations in long-lasting ha formulations. Extending access to emerging markets such as outpatient settings, favorable regulatory support, and Asia-Pacific will further boost demand for increase in demand. Advances such as combination therapy and better distribution methods are also expected to increase the results of treatment and make market access wider. Key Growth Drivers and Opportunities Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals. Challenges The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent. Innovation and Expansion JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Inventive Sparks, Expanding Markets Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
